Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt
The purpose of this study was to explore the value of using cefepime and ceftazidime in treating patients with COVID-19. A total of 370 (162 males) patients, with RT-PCR-confirmed cases of COVID-19, were included in the study. Out of them, 260 patients were treated with cefepime or ceftazidime, with...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/615e678e05074b5392fbb8235de5f5f0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:615e678e05074b5392fbb8235de5f5f0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:615e678e05074b5392fbb8235de5f5f02021-11-25T16:21:51ZEfficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt10.3390/antibiotics101112782079-6382https://doaj.org/article/615e678e05074b5392fbb8235de5f5f02021-10-01T00:00:00Zhttps://www.mdpi.com/2079-6382/10/11/1278https://doaj.org/toc/2079-6382The purpose of this study was to explore the value of using cefepime and ceftazidime in treating patients with COVID-19. A total of 370 (162 males) patients, with RT-PCR-confirmed cases of COVID-19, were included in the study. Out of them, 260 patients were treated with cefepime or ceftazidime, with the addition of steroids to the treatment. Patients were divided into three groups: Group 1: patients treated with cefepime (124 patients); Group 2: patients treated with ceftazidime (136 patients); Group 3 (control group): patients treated according to the WHO guidelines and the Egyptian COVID-19 management protocol (110 patients)/ Each group was classified into three age groups: 18–30, 31–60, and >60 years. The dose of either cefepime or ceftazidime was 1000 mg twice daily for five days. Eight milligrams of dexamethasone were used as the steroidal drug. Careful follow-ups for the patients were carried out. In vitro and in silico M<sup>pro</sup> enzyme assays were performed to investigate the antiviral potential of both antibiotics. The mean recovery time for Group 1 was 12 days, for Group 2 was 13 days, and for Group 3 (control) was 19 days. No deaths were recorded, and all patients were recovered without any complications. For Group 1, the recovery time was 10, 12, and 16 days for the age groups 18–30, 30–60, and >60 years, respectively. For Group 2, the recovery time was 11, 13, and 15 days for the age groups 18–30, 30–60, and >60 years, respectively. For Group 3 (control), the recovery time was 15, 16, and 17 days for the age groups 18–30, 30–60, and >60 years, respectively. Both ceftazidime and cefepime showed very good inhibitory activity towards SARS CoV-2′s M<sup>pro</sup>, with IC<sub>50</sub> values of 1.81 µM and 8.53 µM, respectively. In conclusion, ceftazidime and cefepime are efficient for the management of moderate and severe cases of COVID-19 due to their potential anti-SARS CoV-2 activity and low side effects, and, hence, the currently used complex multidrug treatment protocol can be replaced by the simpler one proposed in this study.Ragaey A. EidMarwa O. ElgendyAhmed O. El-GendySara O. ElgendyLassaad BelbahriAhmed M. SayedMostafa E. RatebMDPI AGarticleceftazidimecefepimeSARS CoV-2M<sup>Pro</sup>COVID-19in silicoTherapeutics. PharmacologyRM1-950ENAntibiotics, Vol 10, Iss 1278, p 1278 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
ceftazidime cefepime SARS CoV-2 M<sup>Pro</sup> COVID-19 in silico Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
ceftazidime cefepime SARS CoV-2 M<sup>Pro</sup> COVID-19 in silico Therapeutics. Pharmacology RM1-950 Ragaey A. Eid Marwa O. Elgendy Ahmed O. El-Gendy Sara O. Elgendy Lassaad Belbahri Ahmed M. Sayed Mostafa E. Rateb Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt |
| description |
The purpose of this study was to explore the value of using cefepime and ceftazidime in treating patients with COVID-19. A total of 370 (162 males) patients, with RT-PCR-confirmed cases of COVID-19, were included in the study. Out of them, 260 patients were treated with cefepime or ceftazidime, with the addition of steroids to the treatment. Patients were divided into three groups: Group 1: patients treated with cefepime (124 patients); Group 2: patients treated with ceftazidime (136 patients); Group 3 (control group): patients treated according to the WHO guidelines and the Egyptian COVID-19 management protocol (110 patients)/ Each group was classified into three age groups: 18–30, 31–60, and >60 years. The dose of either cefepime or ceftazidime was 1000 mg twice daily for five days. Eight milligrams of dexamethasone were used as the steroidal drug. Careful follow-ups for the patients were carried out. In vitro and in silico M<sup>pro</sup> enzyme assays were performed to investigate the antiviral potential of both antibiotics. The mean recovery time for Group 1 was 12 days, for Group 2 was 13 days, and for Group 3 (control) was 19 days. No deaths were recorded, and all patients were recovered without any complications. For Group 1, the recovery time was 10, 12, and 16 days for the age groups 18–30, 30–60, and >60 years, respectively. For Group 2, the recovery time was 11, 13, and 15 days for the age groups 18–30, 30–60, and >60 years, respectively. For Group 3 (control), the recovery time was 15, 16, and 17 days for the age groups 18–30, 30–60, and >60 years, respectively. Both ceftazidime and cefepime showed very good inhibitory activity towards SARS CoV-2′s M<sup>pro</sup>, with IC<sub>50</sub> values of 1.81 µM and 8.53 µM, respectively. In conclusion, ceftazidime and cefepime are efficient for the management of moderate and severe cases of COVID-19 due to their potential anti-SARS CoV-2 activity and low side effects, and, hence, the currently used complex multidrug treatment protocol can be replaced by the simpler one proposed in this study. |
| format |
article |
| author |
Ragaey A. Eid Marwa O. Elgendy Ahmed O. El-Gendy Sara O. Elgendy Lassaad Belbahri Ahmed M. Sayed Mostafa E. Rateb |
| author_facet |
Ragaey A. Eid Marwa O. Elgendy Ahmed O. El-Gendy Sara O. Elgendy Lassaad Belbahri Ahmed M. Sayed Mostafa E. Rateb |
| author_sort |
Ragaey A. Eid |
| title |
Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt |
| title_short |
Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt |
| title_full |
Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt |
| title_fullStr |
Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt |
| title_full_unstemmed |
Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt |
| title_sort |
efficacy of ceftazidime and cefepime in the management of covid-19 patients: single center report from egypt |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/615e678e05074b5392fbb8235de5f5f0 |
| work_keys_str_mv |
AT ragaeyaeid efficacyofceftazidimeandcefepimeinthemanagementofcovid19patientssinglecenterreportfromegypt AT marwaoelgendy efficacyofceftazidimeandcefepimeinthemanagementofcovid19patientssinglecenterreportfromegypt AT ahmedoelgendy efficacyofceftazidimeandcefepimeinthemanagementofcovid19patientssinglecenterreportfromegypt AT saraoelgendy efficacyofceftazidimeandcefepimeinthemanagementofcovid19patientssinglecenterreportfromegypt AT lassaadbelbahri efficacyofceftazidimeandcefepimeinthemanagementofcovid19patientssinglecenterreportfromegypt AT ahmedmsayed efficacyofceftazidimeandcefepimeinthemanagementofcovid19patientssinglecenterreportfromegypt AT mostafaerateb efficacyofceftazidimeandcefepimeinthemanagementofcovid19patientssinglecenterreportfromegypt |
| _version_ |
1718413202412273664 |